Lebrikizumab in the personalized management of asthma

Tools

Thomson, Neil C and Patel, Manish and Smith, Andrew D (2012) Lebrikizumab in the personalized management of asthma. Biologics: Targets and Therapy, 6. pp. 329-335. ISSN 1177-5491 (https://doi.org/10.2147/BTT.S28666)

[thumbnail of Thomson-etal-BTT-2012-Lebrikizumab-in-the-personalized-management-of-asthma]
Preview
 Text. Filename: Thomson_etal_BTT_2012_Lebrikizumab_in_the_personalized_management_of_asthma.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 3.0 logo
Download (752kB)| Preview

Abstract

There is a need for improved therapies for severe asthma. Lebrikizumab, a humanized monoclonal antibody that binds to interleukin (IL)-13, is under development for the treatment of poorly controlled asthma. This article reviews the potential role of IL-13 in the pathogenesis of asthma, the efficacy and safety of lebrikizumab in humans, and progress in patient selection for lebrikizumab therapy. IL-13 is a T-helper (Th2) cell-derived cytokine implicated in inflammatory responses in asthma, including serum immunoglobulin-E synthesis, mucus hypersecretion, and subepithelial fibrosis. Blocking the pro-inflammatory effects of IL-13 with lebrikizumab has the potential to improve asthma control. Published data on the efficacy and safety of lebrikizumab in the treatment of asthma are relatively limited. The late asthmatic response after inhaled allergen challenge is reduced by almost 50%, following treatment with lebrikizumab. In a Phase II study performed in 219 adults with poorly controlled asthma despite inhaled corticosteroids (MILLY trial), lebrikizumab produced an improvement in prebronchodilator forced expiratory volume in 1 second of 5.5% compared with placebo at 12 weeks, but had no effects on other efficacy end points. Adverse effects were similar to placebo, except that musculoskeletal side effects occurred slightly more often with lebrikizumab. Stratifying patients into a high Th2 phenotype using serum periostin, which is upregulated in lung epithelial cells by IL-13, may identify individuals responsive to blockade of IL-13. In the MILLY trial, lebrikizumab treatment was associated with greater improvement in lung function in patients with elevated serum periostin levels compared with those with low periostin levels. Two large Phase III randomized controlled trials in patients with uncontrolled asthma are underway to establish the safety and efficacy of lebrikizumab when administered over a 52-week period. These studies will also help to determine whether identifying patients with a Th2 high inflammatory phenotype using serum periostin allows a personalized approach to the treatment of asthma.

ORCID iDs

Thomson, Neil C, Patel, Manish ORCID logoORCID: https://orcid.org/0000-0003-3012-7507 and Smith, Andrew D;
CORE (COnnecting REpositories)